酞普兰:审查的使用管理的抑郁和焦虑障碍。

文章的细节

引用

复制到剪贴板

沃J,果阿KL

酞普兰:审查的使用管理的抑郁和焦虑障碍。

中枢神经系统药物。2003;17 (5):343 - 62。

PubMed ID

12665392 (在PubMed

]

文摘

酞RS-citalopram的治疗活性s对映体,是一个常用SSRI。R-enantiomer本质上是药物活性。酞10或20毫克/天产生明显能改善测量标准的抗抑郁效果(内在蒙哥马利抑郁量表(MADRS),临床改善全球印象和严重程度量表(CGI-I和CGI-S)和汉密尔顿抑郁量表(ham - d))重度抑郁症患者比安慰剂(MDD)在几个8周,安慰剂对照、随机、双盲、多中心研究。症状改善快,一些参数改善酞普兰治疗开始的1 - 2周内。此外,酞早些时候显示和清晰的分离比RS-citalopram安慰剂,四分之一到一半的剂量,在8周,安慰剂对照试验;子组的疗效明显优于RS-citalopram患者中度MDD在24周的审判;和生产持续反应和缓解患者显著高于文拉法辛延长释放MDD。酞减少复发率与安慰剂比较,增加了长期缓解的患者比例试验(52周)。一直为所有功效显著改善参数也普遍焦虑障碍患者中观察到,社交焦虑障碍和恐慌症处理酞8 - 12周的个体,随机,安慰剂对照,双盲调查。良好的耐受性酞是可预测和RS-citalopram相似。 Such adverse events as nausea, ejaculatory problems, diarrhoea and insomnia are expected but, with the exception of ejaculatory problems and nausea, which is mild and transient, these were generally no more frequent than with placebo in fully published clinical trials. No adverse events not previously seen in acute trials were reported with long-term use. CONCLUSIONS: Escitalopram, the S-enantiomer of RS-citalopram, is a highly selective inhibitor for the serotonin transporter, ameliorates depressive symptoms in patients with MDD at half the RS-citalopram dosage, has a rapid onset of symptom improvement and has a predictable tolerability profile of generally mild adverse events. Like RS-citalopram, escitalopram is expected to have a low propensity for drug interactions, a potential benefit in the management of patients with comorbidities. In combination, these properties place escitalopram, like other SSRIs, as first-line therapy in patients with MDD. Escitalopram is indicated for use in patients with panic disorder in Europe and, should further evidence confirm early findings that escitalopram reduces anxiety, the drug may well find an additional role in the management of anxiety disorders.

beplay体育安全吗DrugBank数据引用了这篇文章

药物靶点

药物	目标	类	生物	药理作用	行动
酞	Sodium-dependent羟色胺转运体	蛋白质	人类	是的	抑制剂	细节